Endpoints News

China seeks to copy the world's most expensive drugs		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T Wed Th F

11 March, 2026

Is your biologics discovery built to maximize the impact of AI?

sponsored by Cradle

presented by

Southern Star Research expands Asia footprint through strategic investment in Expecto Health Science

spotlight

Watch: Who won the Hims vs. Novo feud?

news

RA Capital, Forbion appear to back Harbour's CTLA-4 partner Solstice

China is going after the world's most expensive drugs: Endpoints Signal

Study suggests non-coding RNA, long considered genomic dark matter, has potential in anti-inflammation

Mar 24

11:30 am ET

From structure to selectivity: Federated AI for collaborative binding affinity prediction

in case you missed it

Lundbeck CEO talks drug pricing, protecting biotech and how Europe needs to 'step up'

BioNTech co-founders to exit company and start a new one

Vertex’s kidney drug clears a critical Phase 3 test. Does it still have Humira-like potential?

FDA widens use of leucovorin based on external controls, no new trial data

News Briefing

Ascletis touts GLP-1 quarterly dosing data; Mineralys apnea Phase 2 misses

Breakout Ventures closes $114M fund, with plans for about 20 investments

Trump’s Drug Cost Push Helps Astellas Win Higher Price in Japan

Gerresheimer delays 2025 results to June amid probes, stock to be removed from SDAX

Catch up on the latest from the Hims-Novo saga in our latest edition of Post-Hoc Live. Our reporters talk about what was at stake for both companies before they ended their feud, and the ripple effect of their compounding battle on the industry.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com